Treatment of chronic hepatitis B: New antiviral therapies

Yao, Francis Y.; Gish, Robert G.

doi:10.1007/s11894-999-0082-7

Cited by 7 publications

(3 citation statements)

References 97 publications

(95 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients also were excluded if they were pregnant; if they had a total leukocyte count of <2500 cells/mm 3 , a neutrophil granulocyte count of <1000 cells/mm 3 , a platelet count of <100,000 cells/mL, or a hemoglobin level of <10 g/dL; or if they were unable to provide informed consent.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of lamivudine - α-interferon combination and α-interferon alone treatments in adult patients with naive HBeAg negative hepatitis B

Çelen¹

2011

J Microbiol Infect Dis

View full text Add to dashboard Cite

Objectives: This study aimed to compare the efficacy of the α-interferon treatment with α-interferon plus lamivudine for cases of chronic hepatitis B. Materials and methods:Sixty-one HBeAg negative naive chronic hepatitis B patients were randomly evaluated in two groups prospectively. In group 1, 30 patients were simultaneously given α-interferon 2a 9 MU, 3 days a week by s.c. injection plus lamivudine 100 mg a day for 12 months. In group II, there were 31 patients who only was received the same dosage of α-interferon and no lamivudine over the same period of time. Results:In group 1 the initial mean value of alanine aminotransferase (ALT) was 144±59 IU/L and decreased to 38.8±19.3 IU/L; in group II, initial mean values of ALT was 141±52 IU/L and decreased to 53.2±14.7 IU/L at the end of 12 th month of the therapy (P<0.05). Hepatitis B virus DNA (HBV-DNA) clearance was obtained in 13 of 30 patients (43.3%) in group I patients and 15 of 31 (48.4%) in group II at the end of the therapy (p=0.692). The number of patients with complete response was found to be 14 out of 30 (48.4%) in group 1 and 15 out of 31 cases (46.7%) in group II, six months after the end of the therapy (P=0.893).Conclusion: α-interferon and lamivudine combination therapy had a more beneficial effect than α-interferon monotherapy in normalization of ALT and clearance of HBV-DNA; however, the complete response rate at 6 months after the end of the therapy was not statistically significantly different between both groups. J Microbiol Infect Dis 2011;1(2): 58-63Key words: Chronic hepatitis B, HBeAg negative, combination therapy, α-interferon, lamivudineHBeAg negative erişkin hastalarda lamüvidin-alfa-interferon kombinasyonu ile tek başına alfa-interferon tedavilerinin karşılaştırılması ÖZET Amaç: Bu çalışmada kronik hepatit B hastalarında alfa-interferon ile alfa-interferon + lamivudin kombinasyon tedavisinin etkinliğinin karşılaştırılmasını amaçladık. Gereç ve yöntem:Altmış bir HBeAg negatif naif, kronik hepatit B hastası, rastgele, ileriye dönük olarak iki gruba ayrıldı. Birinci grup, 30 hastaya aynı anda haftada 3 gün subkütan alfa-interferon 2a 9 MU ve günlük 100 mg lamivudin 12 ay boyunca verildi. 2. grup, 31 hasta ise sadece aynı dozlarda alfa-interferon aldı ve hiç biri lamivudin kullanmadı. Sonuç: Alfa-interferon ve lamivudin kombinasyon tedavisi ALT normalleşmesi ve HBV DNA'nın temizlenmesinde alfainterferon monoterapisinden daha yararlı etkisi olup, her iki grupta, tedavi sonrası altı ay sonundaki kalıcı yanıt oranları arasında istatistiksel olarak anlamlı bir fark saptanmadı.Anahtar kelimeler: Kronik hepatit B, HBeAg negatif, kombinasyon tedavisi, alfa-interferon, lamivudin Çelen MK, et al. Treatment of HBV infection in adult patients59

show abstract

Section: Methodsmentioning

confidence: 99%

“…Alfa-interferon is effective in patients with hepatitis B with long lasting response rate. 3 Studies in Asia showed a much lower response rate at 10-20%. [4][5] More than 50% of the patients with CHB infection do not respond to α-interferon treatment and require alternative therapies.…”

Section: Introductionmentioning

confidence: 99%

Comparison of lamivudine - α-interferon combination and α-interferon alone treatments in adult patients with naive HBeAg negative hepatitis B

Çelen¹

2011

J Microbiol Infect Dis

View full text Add to dashboard Cite

show abstract

“…Chronic hepatitis B (CHB) infection is the primary cause of cirrhosis and hepatocellular carcinoma worldwide. α‐Interferon has been shown to be effective in approximately one‐third of patients and response to treatment seems to be sustained in long‐term follow‐up studies conducted in developed countries 1 . Studies in Asia showed a much lower response rate at 10−20% 2,3 .…”

mentioning

confidence: 99%

Comparison of treatments of chronic hepatitis B in children with lamivudine and α‐interferon combination and α‐interferon alone

Dikici¹,

Boşnak²,

Boşnak

et al. 2002

Pediatrics International

View full text Add to dashboard Cite

show abstract

Antiviral Agents

Hosmane

2003

Kirk-Othmer Encyclopedia of Chemical Technology

View full text Add to dashboard Cite

Since the discovery of the first virus >100 years ago, thousands of different viruses have been identified and characterized, and a number of plant, animal, and human ailments have been traced to viral origin. The rapid advances made in tools and techniques of molecular biology in the last 40 years, coupled with cooperative efforts in genetics and biochemical fronts, have afforded intricate details of the structure, function, replication, and genomic makeup of a host of viruses. As there are too many viruses to give even short accounts, this article focuses on only those that have some relevance to human diseases. But, since the list of all human viruses would still be too long to give detailed descriptions for each, the focus is further narrowed down to four major viruses that are currently perceived to threaten global health. These four viruses include HIV (human immunodeficiency virus, which causes AIDS), HBV and HCV (hepatitis B and C viruses that cause liver damage), and the more recent WNV (West Nile virus that causes brain inflammation). Nevertheless, an attempt has been made to classify all the known major viruses based on their shape, size, symmetry, hosts, and chemical composition that includes nucleic acid, protein, and presence or absence of lipid envelope. As they are a form of life that cannot replicate outside a host cell, viruses have evolved to develop complex and diverse interactions with higher organisms. Therefore, it was long believed that the development of antiviral agents that would specifically disrupt the viral replication process without affecting the normal metabolic events of the host would be difficult. Thanks to excellent advances in virology, several targets that are unique to the viruses have now been identified and successfully explored. This article briefly describes the general processes of viral infection to point out potential targets for selective antiviral agents. These targets are then classified into two major virus‐specific processes, including ( a ) early events of viral adsorption, penetration and uncoating, and ( b ) later synthetic events that concern intracellular replication of the virus. While there are only limited choices of candidates dealing with the early events, a much larger pool of candidates exists for targeting the later events in a virus life cycle, and they are known to be virus‐specific. The viruses synthesize and utilize specific enzymes and proteins, and more importantly, the replication of viral genomes is also virus‐specific. Nucleoside analogues which target these later events of viral life cycles have played major roles as antiviral agents against almost all the major viruses, and therefore, a special emphasis has been placed on this class of compounds in this review article. Prophylactic measures such as vaccine immunization have also been discussed under each of the four major viruses mentioned.

show abstract

Treatment of chronic hepatitis B: New antiviral therapies

Cited by 7 publications

References 97 publications

Comparison of lamivudine - α-interferon combination and α-interferon alone treatments in adult patients with naive HBeAg negative hepatitis B

Comparison of lamivudine - α-interferon combination and α-interferon alone treatments in adult patients with naive HBeAg negative hepatitis B

Comparison of treatments of chronic hepatitis B in children with lamivudine and α‐interferon combination and α‐interferon alone

Antiviral Agents

Contact Info

Product

Resources

About